Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
1.355
-0.055 (-3.90%)
At close: May 11, 2026, 4:00 PM EDT
1.360
+0.005 (0.37%)
Pre-market: May 12, 2026, 4:50 AM EDT
PACB Stock Forecast
Stock Price Forecast
The 3 analysts that cover PACB stock have a consensus rating of "Hold" and an average price target of $1.83, which forecasts a 35.06% increase in the stock price over the next year. The lowest target is $1.50 and the highest is $2.00.
Price Target: $1.83 (+35.06%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for PACB stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 3 | 3 | 3 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Sell Maintains $1 → $1.5 | Sell | Maintains | $1 → $1.5 | +10.70% | May 11, 2026 |
| Barclays | Barclays | Sell Maintains $1.5 → $1 | Sell | Maintains | $1.5 → $1 | -26.20% | Apr 14, 2026 |
| Barclays | Barclays | Hold → Sell Downgrades $2 → $1.5 | Hold → Sell | Downgrades | $2 → $1.5 | +10.70% | Mar 6, 2026 |
| Barclays | Barclays | Hold Maintains $1.5 → $2 | Hold | Maintains | $1.5 → $2 | +47.60% | Dec 15, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $1.5 → $2 | Hold | Maintains | $1.5 → $2 | +47.60% | Nov 11, 2025 |
Financial Forecast
Revenue This Year
176.84M
from 160.01M
Increased by 10.52%
Revenue Next Year
199.49M
from 176.84M
Increased by 12.81%
EPS This Year
-0.52
from -1.82
EPS Next Year
-0.42
from -0.52
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 184.8M | 210.0M | |||||
| Avg | 176.8M | 199.5M | |||||
| Low | 164.6M | 186.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 15.5% | 18.8% | |||||
| Avg | 10.5% | 12.8% | |||||
| Low | 2.9% | 5.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | -0.49 | -0.25 | ||||
| Avg | -0.52 | -0.42 | ||||
| Low | -0.53 | -0.46 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.